NCT07273656尚未招募3 期
Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead
University Hospital, Lille0 个研究点目标入组 59 人开始时间: 2026年11月30日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 59
- 主要终点
- Complete clearance of actinic keratosis
研究概览
简要总结
The aim of the study is to evaluate the efficacy and safety of a combined approach of cryotherapy and tirbanibulin for the treatment of actinic keratosis of the scalp and forehead, repeated every 4 months. A higher rate of complete response is expected with this combination compared to cryotherapy alone, as well as a better response with repeated treatment cycles.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
One single group, each patient serving as their own control, with an intra-individual comparison of one hemiscalp with the contralateral hemiscalp
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject over 18 years old presenting with ≥ 8 typical actinic keratoses (AK), clinically visible or palpable, grade I or II, with at least 4 AK per hemiscalp,
- •Participants who, in the investigator's judgment, are in good general condition (ECOG ≤ 2),
- •The AK must be distributed in 2 non-overlapping areas, and of similar grades,
- •Patient capable of understanding and adhering to the study visit schedule and other protocol requirements,
- •Patient capable of understanding and voluntarily signing informed consent,
- •Patient covered by social insurance,
- •Patient willing to comply with all study procedures and duration,
- •Women of childbearing potential must:
- •Have a negative pregnancy test at screening and during the treatment period,
- •Use an effective contraceptive method throughout the study participation. Menopausal women (absence of menstruation for at least one year without other medical cause) or surgically sterile women (tubal ligation, hysterectomy, or bilateral oophorectomy) may be enrolled.
排除标准
- •Clinically atypical and/or rapidly evolving actinic keratoses (AK) in the treatment area, and grade 3 AK according to Olsen classification,
- •A defined treatment area that would be:
- •Located somewhere other than the scalp and/or forehead,
- •Within 5 cm of a wound that is not fully healed or a lesion suspicious for carcinoma,
- •Prior treatment with tirbanibulin,
- •Treatment with 5-fluorouracil (5-FU), imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, or other treatments for actinic keratoses in the treatment area or within 2 cm around this area within 6 weeks prior to the screening visit,
- •Use of the following therapies within 2 weeks prior to the screening visit:
- •Therapeutic or cosmetic procedures (e.g., liquid nitrogen application, surgical excision, dermabrasion, medium or deep chemical peeling, laser resurfacing) in the treatment area or within 2 cm around the selected treatment area,
- •Therapeutic products containing acids (e.g., salicylic acid, fruit acids), topical retinoids, or light peels in the treatment area or within 2 cm around the selected treatment area,
- •Allergy to tirbanibulin or any of its components.
- •Any condition causing a risk of poor compliance,
- •Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage, refusal to sign the consent form,
- •Women of childbearing potential who refuse to use an effective contraceptive method,
- •Pregnant women, women planning to become pregnant, and breastfeeding women,
- •Persons deprived of liberty by judicial or administrative decision.
研究组 & 干预措施
Control group
Placebo Comparator
Cryotherapy + placebo : Tirbanibulin ointment applied once daily for 5 days, repeated 3 times (every 4 months)
干预措施: Cryotherapy + Tirbanibulin (Drug)
Experimental group
Experimental
Cryotherapy + Tirbanibulin : Tirbanibulin ointment applied once daily for 5 days, repeated 3 times (every 4 months)
干预措施: Cryotherapy + Tirbanibulin (Drug)
结局指标
主要结局
Complete clearance of actinic keratosis
时间窗: 8 months
Complete clearance rate of actinic keratoses at 8 months. A complete response corresponds to the absence of clinically detectable actinic keratosis in the treated area.
次要结局
- To evaluate the reduction in the need for cryotherapy with tirbanibulin.(12 months)
- To describe the safety and tolerability by treated side at each follow-up visit.(12 months)
- To evaluate the reduction in the number of actinic keratoses after 2 treatment cycles.(8 months)
- To evaluate the reduction in the number of actinic keratoses after 3 treatment cycles.(12 months)
- To determine the 12-month effectiveness of a combined approach using cryotherapy and tirbanibulin.(12 months)
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of Cryotherapy followed by Tirbanibulin ointment for actinic keratosis on the scalp and foreheadCTIS2023-509931-15-00Centre Hospitalier Universitaire De Lille59
招募中
4 期
Efficacy and Safety of Cryotherapy followed by Tirbanibulin ointment for actinic keratosis on the scalp and forehead2023-509931-15-00Centre Hospitalier Universitaire De Lille59
Unknown
3 期
Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common WartsCommon WartNCT04288817Assiut University40
尚未招募
4 期
Usefulness and safetyOf Cryotherapy versus Bleomycin injection in the treatment of localised keloids.CTRI/2020/08/027352Bankura Sammilani Medical College51
已完成
不适用
Salvage cryotherapy for the localized recurrence prostate cancer after definitive radiotherapy, a prospective studyThe local recurrence prostatse cancer after definitive radiotherapyJPRN-UMIN000018222Jikei University School of Medicine10